Research programme: TGF-beta inhibiting protein gene therapy - Zenith Epigenetics CorpAlternative Names: TGF-β Shield™
Latest Information Update: 14 Jun 2013
At a glance
- Originator Resverlogix Corporation
- Class Gene therapies
- Mechanism of Action Gene transference; Transforming growth factor beta inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer